论文部分内容阅读
目的:观察托泊替康联合顺铂治疗晚期复发性卵巢癌的疗效及毒副反应.方法:28例经病理或细胞学证实为晚期复发性卵巢癌患者予托泊替康0.75~1.2 mg/m2加入0.9%氯化钠100 ml中,静脉滴注30 min,d1-3;顺铂60~75 mg/m2加入0.9%氯化钠500 ml中,静脉滴注,dl.21 d为1周期,2周期为1疗程.结果:28例患者中CR 1例,PR 5例,SD 18例,PD 4例,总有效率为21.4%(6/28).毒副反应主要为骨髓抑制和脱发.结论:托泊替康联合顺铂是治疗晚期复发性卵巢癌疗效较好的方案.“,”Objective To evaluate the therapeutic and adverse effects of topotecan combined with cisplatin in the treatment of advanced recurrent ovarian cancer.Methods Totaly 28 patients with advanced recurrent ovarian cancer, which were confirmed by tissue pathology or cytopathology, were treated with intravenous infusion of topotecan at the dose of 0.75~1.2 mg/m2 (for 3 consecutive days)combined with intravenous infusion of cisplantin at 60~75 mg/m2 for one day. Each treatment course consisted of two 21-day cycles of the treatment. Results In these patients,1 patients had complete remission and 5 patients had partial remission,18 had clinicaly stabilized disease and 4 had progressive disease.The total response rate was 21.4%among the patients. The major adverse efects were bone marrow suppression and alopecia. Conclusion Topotecan plus cisplatin is a better regimen for the treatment of advanced recurrent ovarian cancer.